US2011020381A1PendingUtilityA1

Influenza vaccine formulation

39
Assignee: VARIATION BIOTECHNOLOGIES INCPriority: Nov 30, 2006Filed: Sep 3, 2010Published: Jan 27, 2011
Est. expiryNov 30, 2026(~0.4 yrs left)· nominal 20-yr term from priority
Inventors:Andrei Ogrel
A61P 37/04C12N 2760/16134A61P 31/16A61K 39/145A61K 2039/55566C07K 14/005A61P 37/00A61K 39/12A61K 2039/55505C12N 2760/16122
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza.

Claims

exact text as granted — not AI-modified
1 . A peptide-based immunogenic composition comprising a peptide which is SEQ ID NO: 25. 
     
     
         2 . The composition of  claim 1  further comprising at least one peptide selected from the group consisting of SEQ ID NOs: 26 to 40. 
     
     
         3 . The composition of  claim 1  further comprising a pharmaceutically-acceptable diluent or carrier. 
     
     
         4 . The composition of  claim 3  further comprising an adjuvant. 
     
     
         5 . The composition of  claim 4  wherein the adjuvant is alum. 
     
     
         6 . An immunogenic composition comprising a mixture of isolated peptides selected from the group consisting of SEQ ID NOs: 25 to 40, said peptides representing variants of at least one variable region of an avian influenza virus HA or HA1 protein, wherein each of said variable regions comprises one or more variable amino acid residues, at least one of said variable amino acid residues is represented by two or more amino acids. 
     
     
         7 . The immunogenic composition of  claim 6 , wherein said one or more variable amino acid residues is represented by three or more amino acids. 
     
     
         8 . The immunogenic composition of  claim 6 , further comprising a peptide selected from the group consisting of SEQ ID NOs: 1 to 24 and 41 to 212. 
     
     
         9 . The composition of  claim 1 , further comprising a peptide selected from the group consisting of SEQ ID NOs: 1 to 24 and 41 to 212. 
     
     
         10 . The composition of  claim 1 , comprising peptides of SEQ ID NOs: 25 to 40. 
     
     
         11 . The composition of  claim 1 , comprising peptides of SEQ ID NOs: 1 to 212. 
     
     
         12 . A method of preventing or treating influenza in a patient, comprising administering to the patient an immunogenically effective amount of the immunogenic composition according to  claim 1 . 
     
     
         13 . A method of preventing or treating influenza in a patient, comprising administering to the patient an immunogenically effective amount of the composition according to  claim 6 . 
     
     
         14 . A kit for use in the prevention or treatment of influenza in a patient, comprising the immunogenic composition according to  claim 1  and instructions for use of the immunogenic composition according to  claim 1  in the prevention or treatment of influenza. 
     
     
         15 . A kit for use in the prevention or treatment of influenza in a patient, comprising the composition according to  claim 6  and instructions for use of the composition according to  claim 6  in the prevention or treatment of influenza.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.